BioCryst Pharmaceuticals Newsroom

Earnings Week Ahead: AMD, PLTR, F, DIS, SHOP, DKNG, AMC, LCID, GOLD, RIVN, and More

Seeking AlphaMay 4 08:00 ET

BioCryst Pharmaceuticals Q1 2025 Earnings Preview

Seeking AlphaMay 2 12:35 ET

Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 2 07:00 ET

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireMay 2 07:00 ET

Express News | BioCryst Appoints Steve Frank to Board of Directors

ReutersMay 1 07:00 ET

Press Release: BioCryst Appoints Steve Frank to Board of Directors

Dow JonesMay 1 07:00 ET

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswireApr 30 07:00 ET

Earnings Preview: BCRX to Report Financial Results on May 05

Moomoo NewsApr 29 21:00 ET

BioCryst Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald

Dow JonesApr 29 08:58 ET · Ratings

Cantor Fitzgerald Initiates BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $20

Moomoo NewsApr 29 06:31 ET · Ratings

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Yahoo FinanceApr 28 10:00 ET

JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsApr 24 01:31 ET · Ratings

BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025

Quiver QuantitativeApr 21 07:14 ET

BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsApr 18 00:31 ET · Ratings

Executive Reshuffles: CVS, NNDM, and DBX

Seeking AlphaApr 12 15:54 ET

RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsApr 12 00:31 ET · Ratings

Express News | RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target

BenzingaApr 11 11:19 ET

AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."

① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.

cls.cnApr 11 07:59 ET

Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsApr 11 00:32 ET · Ratings

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

Yahoo FinanceApr 10 17:21 ET